ArticleNeuro-oncology advances

Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy.

Zineb Belcaid et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.